Lon­za’s mod­est fore­cast for cell and gene ther­a­pies points to un­cer­tain­ty about sec­tor's fu­ture

As Lon­za un­veiled its four-year fi­nan­cial pre­dic­tions on Tues­day, ob­servers were left un­sure about the CD­MO’s cell and gene ther­a­py (CGT) fore­cast. Nonethe­less, they were re­as­sured that the Swiss com­pa­ny’s ADC in­vest­ments ap­pear to be on an up­swing.

Lon­za’s cell and gene di­vi­sion is an­tic­i­pat­ed to gen­er­ate a com­pound an­nu­al growth rate in the “mid-teens” over the next four years end­ing in 2028 (ex­change rates ex­clud­ed), with a core EBIT­DA mar­gin of more than 25%, ac­cord­ing to Lon­za’s Cap­i­tal Mar­kets Day pre­sen­ta­tion. While CGT is “cur­rent­ly gen­er­at­ing low­er mar­gins as ex­pect­ed, we re­main con­fi­dent in their long-term com­mer­cial and ther­a­peu­tic po­ten­tial,” in­ter­im CEO Al­bert Baehny added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER